MY208750A - Pharmaceutical composition comprising parp inhibitors - Google Patents

Pharmaceutical composition comprising parp inhibitors

Info

Publication number
MY208750A
MY208750A MYPI2021002598A MYPI2021002598A MY208750A MY 208750 A MY208750 A MY 208750A MY PI2021002598 A MYPI2021002598 A MY PI2021002598A MY PI2021002598 A MYPI2021002598 A MY PI2021002598A MY 208750 A MY208750 A MY 208750A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
parp inhibitors
solid dispersion
preparation
carrier material
Prior art date
Application number
MYPI2021002598A
Inventor
Jiajia Xu
Hao Chen
Xu Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MY208750A publication Critical patent/MY208750A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

A solid dispersion for PARP inhibitors, comprising a compound represented by formula I and a carrier material, wherein the carrier material comprises polyvinylpyrrolidone. A pharmaceutical composition, comprising a solid dispersion, a filler, a disintegrating agent and a lubricant. A preparation method for the solid dispersion. Use of the solid dispersion or the pharmaceutical composition in the preparation of drugs for treating cancers.
MYPI2021002598A 2018-11-16 2019-11-15 Pharmaceutical composition comprising parp inhibitors MY208750A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811363490 2018-11-16
PCT/CN2019/118714 WO2020098774A1 (en) 2018-11-16 2019-11-15 Pharmaceutical composition comprising parp inhibitors

Publications (1)

Publication Number Publication Date
MY208750A true MY208750A (en) 2025-05-27

Family

ID=69600245

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021002598A MY208750A (en) 2018-11-16 2019-11-15 Pharmaceutical composition comprising parp inhibitors

Country Status (16)

Country Link
US (1) US12318385B2 (en)
EP (1) EP3881846B1 (en)
JP (1) JP7469304B2 (en)
KR (1) KR102912737B1 (en)
CN (3) CN115645370A (en)
AU (1) AU2019379706B2 (en)
BR (1) BR112021009190A2 (en)
CA (1) CA3119401A1 (en)
ES (1) ES3065149T3 (en)
HR (1) HRP20260239T1 (en)
MX (1) MX2021005764A (en)
MY (1) MY208750A (en)
PL (1) PL3881846T3 (en)
TW (1) TWI715291B (en)
UA (1) UA128703C2 (en)
WO (1) WO2020098774A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
LT4243797T (en) 2020-11-16 2026-06-10 Orcosa Inc. RAPID INFUSION PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS
CN112843007A (en) * 2021-02-04 2021-05-28 石药集团中奇制药技术(石家庄)有限公司 Olapari tablet
AU2022280845A1 (en) * 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
KR20250103773A (en) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pharmaceutically usable salts, crystal forms and preparation methods of nitrogen-containing heterocyclic compounds
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0609386D0 (en) * 2006-05-11 2006-06-21 Active Botan Ltd Treating drug resistant cancers
CN101032464A (en) * 2007-04-01 2007-09-12 杨喜鸿 Combination containing rimonabant and polyvinyl pyrrolidone, solid dispersion and the preparing and medicine application thereof
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102060722B (en) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 Arsenic compound and preparation method and use thereof
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CN102372716A (en) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazone derivative, its preparation method and application in medicine thereof
CN102372698A (en) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazinone derivative and its preparation method and use in medicine
CN102988296A (en) * 2011-09-08 2013-03-27 江苏恒瑞医药股份有限公司 Celecoxib solid dispersion and preparation method thereof
CN104434805B (en) * 2013-09-22 2017-09-29 成都盛迪医药有限公司 A kind of ticagrelor solid dispersions and preparation method thereof
CN104434809B (en) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 A kind of olaparib solid dispersion preparation and preparation method thereof
MX2017011469A (en) 2015-03-10 2018-01-23 Shionogi Inc Solid dispersions.
CN106265580B (en) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 SOMCL-9112 solid dispersion, preparation method thereof and SOMCL-9112 solid preparation containing same

Also Published As

Publication number Publication date
TW202019934A (en) 2020-06-01
CN110840845B (en) 2022-10-21
CN110840845A (en) 2020-02-28
CN115645370A (en) 2023-01-31
KR102912737B1 (en) 2026-01-15
TWI715291B (en) 2021-01-01
AU2019379706A1 (en) 2021-06-17
JP2022507562A (en) 2022-01-18
EP3881846A4 (en) 2022-08-17
PL3881846T3 (en) 2026-03-30
CN115400087A (en) 2022-11-29
US12318385B2 (en) 2025-06-03
MX2021005764A (en) 2021-10-01
EP3881846A1 (en) 2021-09-22
WO2020098774A1 (en) 2020-05-22
UA128703C2 (en) 2024-10-02
ES3065149T3 (en) 2026-05-04
BR112021009190A2 (en) 2021-08-17
US20210393626A1 (en) 2021-12-23
HRP20260239T1 (en) 2026-03-27
CA3119401A1 (en) 2020-05-22
AU2019379706B2 (en) 2025-02-27
JP7469304B2 (en) 2024-04-16
CN115400087B (en) 2023-10-20
EP3881846C0 (en) 2026-01-28
EP3881846B1 (en) 2026-01-28
KR20210092771A (en) 2021-07-26

Similar Documents

Publication Publication Date Title
MX2021005764A (en) Pharmaceutical composition comprising parp inhibitors.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2019012187A (en) An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer.
MX2023008954A (en) Erbb receptor inhibitors.
ZA202007678B (en) Pharmaceutical combination, composition and combination formulation containing glucokinase activator and k-atp channel blocker, preparation method thereof and use thereof
MY196582A (en) PD-1/PD-L1 Inhibitors
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MX2019012038A (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2024000253A (en) Inhibition of smarca2 for treatment of cancer.
JOP20190186A1 (en) Quinazoline compound
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
GEAP202014982A (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914678A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2016007965A (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
PH12020550491A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
MX2016017325A (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MY191297A (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2019003994A (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer.